An interventional study of Remimazolam and Propofol in Gastric Cancer and Postoperative Delirium, sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 1 site in China. Open to participants aged 65 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by The First Affiliated Hospital with Nanjing Medical University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Stomach Neoplasms by The First Affiliated Hospital with Nanjing Medical University — 21 open to participants now, 24 under way, 2 of them phase 3. Stomach Neoplasms · The First Affiliated Hospital with Nanjing Medical University.
Among the 28 studies in Stomach Neoplasms by The First Affiliated Hospital with Nanjing Medical University, this one is the 5th largest by planned enrollment of the 23 interventional ones that give a count, is one of 7 that started in 2026, is one of 5 with no phase, reaches primary completion later than 10 of the 23 other live ones, and was the 24th registered.
3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.
Browse Stomach Neoplasms studies →21 of the 28 studies in Stomach Neoplasms by The First Affiliated Hospital with Nanjing Medical University are open now, in 1 country. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–75
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–85
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 75+
By country, each count listing its studies:
Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.
This study: 65 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 16 · Phase 3 2
First in 2016; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 170 is above the median of 66 across 2,505 interventional studies indexed under Stomach Neoplasms.
Median enrollment 50 across the 23 interventional studies, 222 across the 5 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
The First Affiliated Hospital with Nanjing Medical University is the lead sponsor of 569 studies on the registry; 317 are open to participants now.
10 of the studies in Stomach Neoplasms by The First Affiliated Hospital with Nanjing Medical University that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06939439Phase 3The First Affiliated Hospital with Nanjing Medical UniversityUsing ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer | 2026-12-31 |
| NCT07351474The First Affiliated Hospital with Nanjing Medical UniversityRemimazolam for Reducing Postoperative Delirium in Elderly Patients Undergoing Laparoscopic Gastrectomy | 2026-12-25 |
| NCT07902596The First Affiliated Hospital with Nanjing Medical UniversityLymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma | 2026-12-31 |
| NCT07391826The First Affiliated Hospital with Nanjing Medical UniversityMegestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOX | 2026-12-31 |
| NCT06555471The First Affiliated Hospital with Nanjing Medical UniversityA Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 28 studies in Stomach Neoplasms by The First Affiliated Hospital with Nanjing Medical University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, single-center, randomized, participant- and outcome assessor-blinded, parallel-group controlled trial evaluated whether remimazolam-based anesthesia reduced postoperative delirium (POD) and improved peri-induction hemodynamic stability compared with propofol-midazolam-based anesthesia in patients aged 65 years or older undergoing elective laparoscopic radical gastrectomy for gastric cancer. A total of 147 participants were randomized in a 1:1 ratio. Standardized perioperative management, BIS-guided anesthetic depth control, and postoperative analgesia were applied in both groups. The primary outcome was the cumulative incidence of POD during postoperative days 1-3, assessed once daily using the 3D-CAM or CAM-ICU by trained outcome assessors blinded to treatment allocation. Secondary outcomes included post-induction hypotension, peri-induction hemodynamic variables, postoperative recovery, pain scores, and adverse events.
This prospective, single-center, randomized, participant- and outcome assessor-blinded, parallel-group controlled trial was conducted at the First Affiliated Hospital of Nanjing Medical University between January 21 and August 5, 2026. Patients aged 65 years or older who were scheduled to undergo elective laparoscopic radical gastrectomy for gastric cancer were screened for eligibility. A total of 147 participants were randomized in a 1:1 ratio to receive either remimazolam-based anesthesia or propofol-midazolam-based anesthesia. Randomization was based on a computer-generated sequence, with allocation concealed using sequentially numbered, opaque, sealed envelopes. Participants and postoperative outcome assessors were blinded to treatment allocation, whereas the attending anesthesiologists administering the allocated anesthetic regimen were not blinded.
Standardized perioperative monitoring and management were applied in both groups, including bispectral index-guided anesthetic depth control, opioid analgesia, neuromuscular blockade, controlled ventilation, vasoactive medication titration, and postoperative patient-controlled intravenous analgesia. Postoperative delirium was assessed once daily between 14:00 and 17:00 on postoperative days 1-3. Ward patients were assessed using the 3-Minute Diagnostic Interview for Confusion Assessment Method, whereas patients admitted to the intensive care unit were assessed using the Confusion Assessment Method for the Intensive Care Unit.
The original protocol specified standardized delirium assessment through postoperative day 5. Owing to limited research personnel during trial implementation, standardized assessments could only be consistently completed through postoperative day 3. Therefore, the primary outcome was the cumulative incidence of POD during postoperative days 1-3, and no assumptions were made regarding delirium status on postoperative days 4 and 5. Secondary outcomes included post-induction hypotension, maximum reduction in mean arterial pressure from baseline, peri-induction vasoactive drug requirements, peri-induction mean arterial pressure, heart rate and bispectral index trajectories, time to extubation, length of stay in the post-anesthesia care unit and hospital, postoperative pain scores, postoperative nausea and vomiting, PACU hypoxemia, emergence agitation, unplanned intensive care unit admission, and postoperative pulmonary infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will receive remimazolam for anesthesia induction and maintenance during laparoscopic radical gastrectomy.
Drug: Remimazolam
Participants in this group will receive propofol for anesthesia induction and maintenance during laparoscopic radical gastrectomy.
Drug: Propofol
Remimazolam will be used as the primary anesthetic agent for induction and maintenance. Dosage will be adjusted to maintain BIS between 40 and 60.
Propofol will be used as the primary anesthetic agent for induction and maintenance. Dosage will be adjusted to maintain BIS between 40 and 60.
incidence of Postoperative Delirium
Postoperative delirium will be assessed using the 3D-CAM diagnostic tool by trained evaluators blinded to group assignment. Delirium will be identified based on the presence of acute onset/fluctuation, inattention, altered consciousness, or disorganized thinking, following the standard 3D-CAM algorithm.
Time frame: From postoperative Day 1 to Day 3
Emergence Agitation
Emergence agitation will be assessed in the PACU using the RASS or agitation scale by blinded evaluators.
Time frame: Immediately after extubation until PACU discharge
Time to extubation
Time from discontinuation of anesthetic agents to successful tracheal extubation.
Time frame: At the end of surgery
Postoperative Pain Score
Pain itensity will be evaluated using the Numerical Rating Scale(NRS,0-10)
Time frame: At PACU discharge; postoperative day 1,day 2,and day 3.
Post-induction Hypotension
Post-induction hypotension will be defined as a decrease in mean arterial pressure (MAP) to \<65 mmHg or a reduction of ≥30% from baseline within the first 10 minutes after anesthetic induction.
Time frame: From completion of anesthetic induction to 10 minutes after induction.
Incidence of Postoperative Nausea and Vomiting
Postoperative nausea and vomiting assessed as the presence or absence based on patient reports and medical records during the postoperative period.
Time frame: From surgery until 48 hours postoperatively
Length of Hospital Stay(days)
Length of hospital stay is defined as the number of calendar days from the date of surgery (Day 0) until the date of hospital discharge , as recorded in the electronic medical record system
Time frame: From the day of surgery (Day 0) to the date of hospital discharge (expected within 7-14 days postoperatively)
Plan to share: No
Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.
Of 358 non-industry interventional studies with no phase under Stomach Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 63. This study's planned 11 months is below that.
Counting every sponsor, half of 369 studies reached it within 36 months; a quarter within 17 and three quarters within 63.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Jul 2026 → Dec 2026 and completion Aug 2026 → Jan 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Remimazolam
The First Affiliated Hospital with Nanjing Medical University →